{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:31:22Z","timestamp":1790447482442,"version":"4.1.0"},"reference-count":204,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Smallpox was eradicated in less than 200 years after Edward Jenner\u2019s practice of cowpox variolation in 1796. The forty-three years of us living free of smallpox, beginning in 1979, never truly separated us from poxviruses. The recent outbreak of monkeypox in May 2022 might well warn us of the necessity of keeping up both the scientific research and public awareness of poxviruses. One of them in particular, the vaccinia virus (VACV), has been extensively studied as a vector given its broad host range, extraordinary thermal stability, and exceptional immunogenicity. Unceasing fundamental biological research on VACV provides us with a better understanding of its genetic elements, involvement in cellular signaling pathways, and modulation of host immune responses. This enables the rational design of safer and more efficacious next-generation vectors. To address the new technological advancement within the past decade in VACV research, this review covers the studies of viral immunomodulatory genes, modifications in commonly used vectors, novel mechanisms for rapid generation and purification of recombinant virus, and several other innovative approaches to studying its biology.<\/jats:p>","DOI":"10.3390\/v15081742","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:06:16Z","timestamp":1692097576000},"page":"1742","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&amp;D Advances"],"prefix":"10.3390","volume":"15","author":[{"given":"Yuxiang","family":"Wang","sequence":"first","affiliation":[{"name":"Vaccine Research Center, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"ref_1","unstructured":"Fenner, F., Henderson, D.A., Arita, I., Je\u017eek, Z., and Ladnyi, I.D. (2022, October 08). Smallpox and Its Eradication, Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/39485."},{"key":"ref_2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/infdis\/142.4.636","article-title":"A reality in our time\u2014Certification of the global eradication of smallpox","volume":"142","author":"Wehrle","year":"1980","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1016\/j.vaccine.2020.05.037","article-title":"Early smallpox vaccine manufacturing in the United States: Introduction of the \u201canimal vaccine\u201d in 1870, establishment of \u201cvaccine farms\u201d, and the beginnings of the vaccine industry","volume":"38","author":"Esparza","year":"2020","journal-title":"Vaccine"},{"key":"ref_4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/infdis\/122.4.303","article-title":"Complications of smallpox vaccination, 1968: Results of ten statewide surveys","volume":"122","author":"Lane","year":"1970","journal-title":"J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-138-6-200303180-00014","article-title":"Evaluation of 21st-century risks of smallpox vaccination and policy options","volume":"138","author":"Lane","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_6","first-page":"84","article-title":"Expected adverse events in a mass smallpox vaccination campaign","volume":"5","author":"Kemper","year":"2002","journal-title":"Eff. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/nm916","article-title":"Clonal vaccinia virus grown in cell culture as a new smallpox vaccine","volume":"9","author":"Weltzin","year":"2003","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijid.2004.09.002","article-title":"ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)\u2014A second-generation smallpox vaccine for biological defense","volume":"8","author":"Monath","year":"2004","journal-title":"Int. J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.vaccine.2008.11.079","article-title":"Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults","volume":"27","author":"Frey","year":"2009","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1517\/13543784.17.4.555","article-title":"ACAM2000: A newly licensed cell culture-based live vaccinia smallpox vaccine","volume":"17","author":"Greenberg","year":"2008","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_11","doi-asserted-by":"publisher","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S0140-6736(05)70234-8","article-title":"Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: A blind, single-centre, randomised controlled trial","volume":"365","author":"Greenberg","year":"2005","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"Vollmar","year":"2010","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","volume":"79","author":"Drexler","year":"1998","journal-title":"J. Gen. Virol."},{"key":"ref_16","first-page":"375","article-title":"The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl. Bakteriol. B"},{"key":"ref_17","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1099\/vir.0.2008\/004440-0","article-title":"Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax","volume":"89","author":"Midgley","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_18","first-page":"65","article-title":"Safe and effective poxvirus vectors\u2014NYVAC and ALVAC","volume":"82","author":"Paoletti","year":"1994","journal-title":"Dev. Biol. Stand."},{"key":"ref_19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","article-title":"NYVAC: A highly attenuated strain of vaccinia virus","volume":"188","author":"Tartaglia","year":"1992","journal-title":"Virology"},{"key":"ref_20","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1099\/vir.0.034207-0","article-title":"Serological responses in humans to the smallpox vaccine LC16m8","volume":"92","author":"Johnson","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_21","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","article-title":"LC16m8: An attenuated smallpox vaccine","volume":"24","author":"Kenner","year":"2006","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/0042-6822(91)90480-Y","article-title":"Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins","volume":"181","author":"Funahashi","year":"1991","journal-title":"Virology"},{"key":"ref_23","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/infdis\/jir527","article-title":"Safety and Immunogenicity of LC16m8, an Attenuated Smallpox Vaccine in Vaccinia-Naive Adults","volume":"204","author":"Kennedy","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jama.2009.289","article-title":"Clinical and Immunological Response to Attenuated Tissue-Cultured Smallpox Vaccine LC16m8","volume":"301","author":"Saito","year":"2009","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/infdis\/jiq017","article-title":"Multivalent Smallpox DNA Vaccine Delivered by Intradermal Electroporation Drives Protective Immunity in Nonhuman Primates Against Lethal Monkeypox Challenge","volume":"203","author":"Hirao","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.virol.2007.09.029","article-title":"Immunogenicity and Protection Efficacy of Subunit-based Smallpox Vaccines Using Variola Major Antigens","volume":"371","author":"Sakhatskyy","year":"2008","journal-title":"Virology"},{"key":"ref_28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"key":"ref_29","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.1016\/j.vaccine.2010.07.030","article-title":"A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge","volume":"28","author":"Buchman","year":"2010","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"publisher","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.vaccine.2010.10.064","article-title":"VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone","volume":"29","author":"Moise","year":"2011","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"publisher","first-page":"961","DOI":"10.4161\/hv.21080","article-title":"A vaccinia virus renaissance: New vaccine and immunotherapeutic uses after smallpox eradication","volume":"8","author":"Verardi","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_34","unstructured":"Centers for Disease Control and Prevention (2023, March 22). 2022 Outbreak Cases and Data|Mpox|Poxvirus, Available online: https:\/\/www.cdc.gov\/poxvirus\/mpox\/response\/2022\/index.html."},{"key":"ref_35","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1128\/JVI.02152-17","article-title":"Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles","volume":"92","author":"Liu","year":"2018","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"O\u2019Connell, C.M., Jasperse, B., Hagen, C.J., Titong, A., and Verardi, P.H. (2020). Replication-inducible vaccinia virus vectors with enhanced safety in vivo. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230711"},{"key":"ref_37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev.mi.48.100194.002021","article-title":"Mechanisms underlying expression of Tn10 encoded tetracycline resistance","volume":"48","author":"Hillen","year":"1994","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1084-9521(02)00018-6","article-title":"Tetracycline-controlled transcriptional regulation systems: Advances and application in transgenic animal modeling","volume":"13","author":"Zhu","year":"2002","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_39","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1089\/hum.1998.9.13-1939","article-title":"Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells","volume":"9","author":"Yao","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"ref_40","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.addr.2008.12.016","article-title":"In vivo gene regulation using tetracycline-regulatable systems","volume":"61","author":"Stieger","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_41","doi-asserted-by":"publisher","first-page":"10775","DOI":"10.1073\/pnas.121186498","article-title":"Tetracycline-inducible systems for Drosophila","volume":"98","author":"Stebbins","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1073\/pnas.85.5.1394","article-title":"Tn10-encoded tet repressor can regulate an operator-containing plant promoter","volume":"85","author":"Gatz","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/BF00351693","article-title":"Construction of a tetracycline-inducible promoter in Schizosaccharomyces pombe","volume":"21","author":"Faryar","year":"1992","journal-title":"Curr. Genet."},{"key":"ref_44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1751-7915.2007.00001.x","article-title":"The application of Tet repressor in prokaryotic gene regulation and expression","volume":"1","author":"Bertram","year":"2008","journal-title":"Microb. Biotechnol."},{"key":"ref_45","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1091\/mbc.12.7.2031","article-title":"Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei","volume":"12","author":"Tolonen","year":"2001","journal-title":"Mol. Biol. Cell"},{"key":"ref_46","doi-asserted-by":"publisher","first-page":"9773","DOI":"10.1128\/JVI.76.19.9773-9786.2002","article-title":"The Vaccinia virus E8R gene product: A viral membrane protein that is made early in infection and packaged into the virions\u2019 core","volume":"76","author":"Doglio","year":"2002","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.virol.2007.05.002","article-title":"The vaccinia virus E8R gene product is required for formation of transcriptionally active virions","volume":"367","author":"Kato","year":"2007","journal-title":"Virology"},{"key":"ref_48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.virol.2004.08.038","article-title":"Temperature-sensitive mutants in the vaccinia virus 4b virion structural protein assemble malformed, transcriptionally inactive intracellular mature virions","volume":"330","author":"Kato","year":"2004","journal-title":"Virology"},{"key":"ref_49","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.virol.2015.02.003","article-title":"Poxvirus membrane biogenesis","volume":"479\u2013480","author":"Moss","year":"2015","journal-title":"Virology"},{"key":"ref_50","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1038\/s41598-021-85951-7","article-title":"Single dose of a replication-defective vaccinia virus expressing Zika virus-like particles is protective in mice","volume":"11","author":"Jasperse","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"publisher","first-page":"e00790-17","DOI":"10.1128\/mBio.00790-17","article-title":"Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins","volume":"8","author":"Wyatt","year":"2017","journal-title":"MBio"},{"key":"ref_52","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1073\/pnas.96.6.2692","article-title":"Identification of a transcription factor, encoded by two vaccinia virus early genes, that regulates the intermediate stage of viral gene expression","volume":"96","author":"Sanz","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9514","DOI":"10.1128\/JVI.06902-11","article-title":"Reverse Genetics Analysis of Poxvirus Intermediate Transcription Factors","volume":"86","author":"Warren","year":"2012","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.ymthe.2017.06.017","article-title":"Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology","volume":"25","author":"Eldi","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.3390\/v6103787","article-title":"From crescent to mature virion: Vaccinia virus assembly and maturation","volume":"6","author":"Liu","year":"2014","journal-title":"Viruses"},{"key":"ref_56","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/0042-6822(92)90467-4","article-title":"Immature viral envelope formation is interrupted at the same stage by lac operator-mediated repression of the vaccinia virus D13L gene and by the drug rifampicin","volume":"187","author":"Zhang","year":"1992","journal-title":"Virology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7714","DOI":"10.1128\/JVI.00207-06","article-title":"A poxvirus host range protein, CP77, binds to a cellular protein, HMG20A, and regulates its dissociation from the vaccinia virus genome in CHO-K1 cells","volume":"80","author":"Hsiao","year":"2006","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5.13.1","DOI":"10.1002\/cpps.33","article-title":"Generation of Recombinant Vaccinia Viruses","volume":"89","author":"Wyatt","year":"2017","journal-title":"Curr. Protoc. Protein Sci."},{"key":"ref_59","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1128\/jvi.64.6.3108-3111.1990","article-title":"Transient dominant selection of recombinant vaccinia viruses","volume":"64","author":"Falkner","year":"1990","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-62703-218-6_18","article-title":"Recombinant poxviruses: Versatile tools for immunological assays","volume":"960","author":"Siciliano","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_61","doi-asserted-by":"publisher","first-page":"100918","DOI":"10.1016\/j.mex.2020.100918","article-title":"Application of poxvirus K3 ortholog as a positive selection marker for constructing recombinant vaccinia viruses with modified host range","volume":"7","author":"Cao","year":"2020","journal-title":"MethodsX"},{"key":"ref_62","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.omtm.2020.03.026","article-title":"EPPIC (Efficient Purification by Parental Inducer Constraint) Platform for Rapid Generation of Recombinant Vaccinia Viruses","volume":"17","author":"Jasperse","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_63","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2144\/000113667","article-title":"Use of a negative selectable marker for rapid selection of recombinant vaccinia virus","volume":"50","author":"White","year":"2011","journal-title":"Biotechniques"},{"key":"ref_64","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1093\/emboj\/20.14.3728","article-title":"Heterologous dimerization domains functionally substitute for the double-stranded RNA binding domains of the kinase PKR","volume":"20","author":"Ung","year":"2001","journal-title":"EMBO J."},{"key":"ref_65","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0022-2836(81)90375-2","article-title":"Bacteriophage P1 site-specific recombination. I. Recombination between loxP sites","volume":"150","author":"Sternberg","year":"1981","journal-title":"J. Mol. Biol."},{"key":"ref_66","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1073\/pnas.85.14.5166","article-title":"Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1","volume":"85","author":"Sauer","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Rintoul, J.L., Wang, J., Gammon, D.B., van Buuren, N.J., Garson, K., Jardine, K., Barry, M., Evans, D.H., and Bell, J.C. (2011). A selectable and excisable marker system for the rapid creation of recombinant poxviruses. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024643"},{"key":"ref_68","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.omtm.2017.09.007","article-title":"Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus","volume":"7","author":"Guo","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_69","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1128\/JVI.00339-15","article-title":"Efficiently Editing the Vaccinia Virus Genome by Using the CRISPR-Cas9 System","volume":"89","author":"Yuan","year":"2015","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s42003-020-01374-6","article-title":"Rapid poxvirus engineering using CRISPR\/Cas9 as a selection tool","volume":"3","author":"Gowripalan","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_71","doi-asserted-by":"publisher","first-page":"15035","DOI":"10.1038\/mtm.2015.35","article-title":"A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9","volume":"2","author":"Yuan","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_72","doi-asserted-by":"publisher","first-page":"166896","DOI":"10.1016\/j.jmb.2021.166896","article-title":"MAVERICC: Marker-free vaccinia virus engineering of recombinants through in vitro CRISPR\/Cas9 cleavage","volume":"433","author":"Laudermilch","year":"2021","journal-title":"J. Mol. Biol."},{"key":"ref_73","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1038\/s41598-018-21575-8","article-title":"CRISPR-Cas9, a tool to efficiently increase the development of recombinant African swine fever viruses","volume":"8","author":"Borca","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Bi, Y., Sun, L., Gao, D., Ding, C., Li, Z., Li, Y., Cun, W., and Li, Q. (2014). High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004090"},{"key":"ref_75","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jviromet.2014.11.009","article-title":"Engineering herpes simplex viruses by infection-transfection methods including recombination site targeting by CRISPR\/Cas9 nucleases","volume":"213","author":"Russell","year":"2015","journal-title":"J. Virol. Methods"},{"key":"ref_76","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.cell.2013.08.022","article-title":"One-step generation of mice carrying reporter and conditional alleles by CRISPR\/Cas-mediated genome engineering","volume":"154","author":"Yang","year":"2013","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nbt.2508","article-title":"RNA-guided editing of bacterial genomes using CRISPR-Cas systems","volume":"31","author":"Jiang","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_78","doi-asserted-by":"publisher","first-page":"7435","DOI":"10.1007\/s00253-017-8497-9","article-title":"CRISPR\/Cas9-based genome editing of the filamentous fungi: The state of the art","volume":"101","author":"Shi","year":"2017","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_79","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jeu.12338","article-title":"Genome Editing by CRISPR\/Cas9: A Game Change in the Genetic Manipulation of Protists","volume":"63","author":"Lander","year":"2016","journal-title":"J. Eukaryot. Microbiol."},{"key":"ref_80","doi-asserted-by":"publisher","first-page":"e2009","DOI":"10.1002\/rmv.2009","article-title":"Harnessing CRISPR\/Cas 9 System for manipulation of DNA virus genome","volume":"29","author":"Ebrahimi","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_81","first-page":"65","article-title":"Construction of cDNA libraries in vaccinia virus","volume":"269","author":"Smith","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"ref_82","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1099\/vir.0.055921-0","article-title":"Vaccinia virus immune evasion: Mechanisms, virulence and immunogenicity","volume":"94","author":"Smith","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Albarnaz, J.D., Torres, A.A., and Smith, G.L. (2018). Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory. Viruses, 10.","DOI":"10.3390\/v10030101"},{"key":"ref_84","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/335176a0","article-title":"Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins","volume":"335","author":"Kotwal","year":"1988","journal-title":"Nature"},{"key":"ref_85","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/infdis\/166.6.1245","article-title":"Regulation of complement activity by vaccinia virus complement-control protein","volume":"166","author":"McKenzie","year":"1992","journal-title":"J. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1099\/0022-1317-83-8-1977","article-title":"Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes","volume":"83","author":"Tscharke","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_87","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1091\/mbc.e04-11-1005","article-title":"Quantitative SUMO-1 modification of a vaccinia virus protein is required for its specific localization and prevents its self-association","volume":"16","author":"Palacios","year":"2005","journal-title":"Mol. Biol. Cell"},{"key":"ref_88","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1099\/0022-1317-80-8-2137","article-title":"The vaccinia virus A4OR gene product is a nonstructural, type II membrane glycoprotein that is expressed at the cell surface","volume":"80","author":"Wilcock","year":"1999","journal-title":"J. Gen. Virol."},{"key":"ref_89","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1084\/jem.20041442","article-title":"Vaccinia virus protein A46R targets multiple Toll-like\u2013interleukin-1 receptor adaptors and contributes to virulence","volume":"201","author":"Stack","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Bahar, M.W., Kenyon, J.C., Putz, M.M., Abrescia, N.G.A., Pease, J.E., Wise, E.L., Stuart, D.I., Smith, G.L., and Grimes, J.M. (2008). Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.0040005"},{"key":"ref_91","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1084\/jem.20021652","article-title":"The Poxvirus Protein A52R Targets Toll-like Receptor Signaling Complexes to Suppress Host Defense","volume":"197","author":"Harte","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_92","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-019-0928-6","article-title":"Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS-STING signaling","volume":"566","author":"Eaglesham","year":"2019","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1073\/pnas.0510462103","article-title":"A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus","volume":"103","author":"Alejo","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1099\/0022-1317-83-8-1953","article-title":"A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence","volume":"83","author":"Symons","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_95","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1099\/0022-1317-83-4-873","article-title":"The vaccinia virus B9R protein is a 6 kDa intracellular protein that is non-essential for virus replication and virulence","volume":"83","author":"Price","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_96","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1128\/jvi.70.9.6479-6485.1996","article-title":"Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product","volume":"70","author":"Dobbelstein","year":"1996","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Chen, R.A.J., Ryzhakov, G., Cooray, S., Randow, F., and Smith, G.L. (2008). Inhibition of I\u03baB Kinase by Vaccinia Virus Virulence Factor B14. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.0040022"},{"key":"ref_98","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1099\/vir.0.80646-0","article-title":"Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara","volume":"86","author":"Staib","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_99","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/0092-8674(95)90076-4","article-title":"Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity","volume":"81","author":"Symons","year":"1995","journal-title":"Cell"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Unterholzner, L., Sumner, R.P., Baran, M., Ren, H., Mansur, D.S., Bourke, N.M., Randow, F., Smith, G.L., and Bowie, A.G. (2011). Vaccinia Virus Protein C6 Is a Virulence Factor that Binds TBK-1 Adaptor Proteins and Inhibits Activation of IRF3 and IRF7. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002247"},{"key":"ref_101","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/0042-6822(90)90296-4","article-title":"Vaccinia virus host range genes","volume":"179","author":"Perkus","year":"1990","journal-title":"Virology"},{"key":"ref_102","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.1128\/JVI.02108-05","article-title":"Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene","volume":"80","author":"Gherardi","year":"2006","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"publisher","first-page":"10627","DOI":"10.1128\/JVI.01260-09","article-title":"Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons","volume":"83","author":"Meng","year":"2009","journal-title":"J. Virol."},{"key":"ref_104","first-page":"1223","article-title":"Ectromelia, vaccinia and cowpox viruses encode secreted interleu-kin-18-binding proteins","volume":"81","author":"Smith","year":"2000","journal-title":"J. Gen. Virol."},{"key":"ref_105","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1038\/s41467-023-38514-5","article-title":"Vaccinia E5 is a major inhibitor of the DNA sensor cGAS","volume":"14","author":"Yang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_106","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/emboj.2008.143","article-title":"Viral targeting of DEAD box protein 3 reveals its role in TBK1\/IKK\u025b-mediated IRF activation","volume":"27","author":"Baran","year":"2008","journal-title":"EMBO J."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Teferi, W.M., Desaulniers, M.A., Noyce, R.S., Shenouda, M., Umer, B., and Evans, D.H. (2017). The vaccinia virus K7 protein promotes histone methylation associated with heterochromatin formation. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173056"},{"key":"ref_108","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1743-422X-7-59","article-title":"A poxvirus Bcl-2-like gene family involved in regulation of host immune response: Sequence similarity and evolutionary history","volume":"7","author":"Gonzlez","year":"2010","journal-title":"Virol. J."},{"key":"ref_109","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1099\/vir.0.054114-0","article-title":"Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence","volume":"94","author":"Ferguson","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"P\u00e9rez, P., Mar\u00edn, M.Q., L\u00e1zaro-Fr\u00edas, A., Sorzano, C.\u00d3.S., G\u00f3mez, C.E., Esteban, M., and Garc\u00eda-Arriaza, J. (2020). Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B. Vaccines, 8.","DOI":"10.3390\/vaccines8010070"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Mar\u00edn, M.Q., P\u00e9rez, P., G\u00f3mez, C.E., Sorzano, C.\u00d3.S., Esteban, M., and Garc\u00eda-Arriaza, J. (2018). Removal of the C6 Vaccinia Virus Interferon-\u03b2 Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression. Viruses, 10.","DOI":"10.1101\/330902"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arriaza, J., N\u00e1jera, J.L., G\u00f3mez, C.E., Sorzano, C.O.S., and Esteban, M. (2010). Immunogenic Profiling in Mice of a HIV\/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012395"},{"key":"ref_113","doi-asserted-by":"publisher","first-page":"12605","DOI":"10.1128\/JVI.00246-12","article-title":"Deletion of Specific Immune-Modulatory Genes from Modified Vaccinia Virus Ankara-Based HIV Vaccines Engenders Improved Immunogenicity in Rhesus Macaques","volume":"86","author":"Garber","year":"2012","journal-title":"J. Virol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Perdiguero, B., G\u00f3mez, C.E., Di Pilato, M., Sorzano, C.O.S., Delaloye, J., Roger, T., Calandra, T., Pantaleo, G., and Esteban, M. (2013). Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV\/AIDS Vaccine Candidate NYVAC-C. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074831"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Holgado, M.P., Falivene, J., Maeto, C., Amigo, M., Pascutti, M.F., Vecchione, M.B., Bruttomesso, A., Calamante, G., Del M\u00e9dico-Zajac, M.P., and Gherardi, M.M. (2016). Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses. Viruses, 8.","DOI":"10.3390\/v8050139"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"G\u00f3mez, C.E., Perdiguero, B., S\u00e1nchez-Corzo, C., Sorzano, C.O.S., and Esteban, M. (2018). Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways. Viruses, 10.","DOI":"10.3390\/v10010007"},{"key":"ref_117","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1073\/pnas.1424341112","article-title":"NF\u03baB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses","volume":"112","author":"Zonca","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JVI.00575-17","article-title":"Distinct Roles of Vaccinia Virus NF-\u03baB Inhibitor Proteins A52, B15, and K7 in the Immune Response","volume":"91","author":"Sorzano","year":"2017","journal-title":"J. Virol."},{"key":"ref_119","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/s41417-023-00610-5","article-title":"Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease","volume":"30","author":"Riederer","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_120","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1128\/JVI.06684-11","article-title":"Removal of Vaccinia Virus Genes That Block Interferon Type I and II Pathways Improves Adaptive and Memory Responses of the HIV\/AIDS Vaccine Candidate NYVAC-C in Mice","volume":"86","author":"Gomez","year":"2012","journal-title":"J. Virol."},{"key":"ref_121","doi-asserted-by":"publisher","first-page":"e01648-18","DOI":"10.1128\/JVI.01648-18","article-title":"Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses","volume":"93","author":"Chea","year":"2019","journal-title":"J. Virol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arriaza, J., N\u00e1jera, J.L., G\u00f3mez, C.E., Tewabe, N., Sorzano, C.O.S., Calandra, T., Roger, T., and Esteban, M. (2011). A candidate HIV\/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024244"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arriaza, J., Arn\u00e1ez, P., G\u00f3mez, C.E., Sorzano, C.\u00d3.S., and Esteban, M. (2013). Improving Adaptive and Memory Immune Responses of an HIV\/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066894"},{"key":"ref_124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2016.03.007","article-title":"NYVAC vector modified by C7L viral gene insertion improves T cell immune responses and effectiveness against leishmaniasis","volume":"220","author":"SSorzano","year":"2016","journal-title":"Virus Res."},{"key":"ref_125","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1128\/JVI.02723-13","article-title":"Deletion of the Vaccinia Virus N2L Gene Encoding an Inhibitor of IRF3 Improves the Immunogenicity of Modified Vaccinia Virus Ankara Expressing HIV-1 Antigens","volume":"88","author":"Gomez","year":"2014","journal-title":"J. Virol."},{"key":"ref_126","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.1016\/j.vaccine.2015.07.113","article-title":"Vaxvec: The first web-based recombinant vaccine vector database and its data analysis","volume":"33","author":"Deng","year":"2015","journal-title":"Vaccine"},{"key":"ref_127","doi-asserted-by":"publisher","first-page":"D1124","DOI":"10.1093\/nar\/gkt1133","article-title":"Updates on the web-based VIOLIN vaccine database and analysis system","volume":"42","author":"He","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_128","doi-asserted-by":"publisher","first-page":"D923","DOI":"10.1093\/nar\/gkm1039","article-title":"VIOLIN: Vaccine investigation and online information network","volume":"36","author":"Xiang","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_129","unstructured":"Perdiguero, B., G\u00f3mez, C.E., and Esteban, M. (2020, September 17). Bioluminescence Imaging as a Tool for Poxvirus Biology. Methods in Molecular Biology, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/31240684\/."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-4939-9593-6_14","article-title":"Visualizing Poxvirus Replication and Recombination Using Live-Cell Imaging","volume":"2023","author":"Kieser","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Gallardo, F., Schmitt, D., Brandely, R., Brua, C., Silvestre, N., Findeli, A., Foloppe, J., Top, S., Kappler-Gratias, S., and Quentin-Froignant, C. (2020). Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators. Biomedicines, 8.","DOI":"10.3390\/biomedicines8120543"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-4939-9593-6_13","article-title":"Click Chemistry-Based Labeling of Poxvirus Genomes","volume":"2023","author":"Mok","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_133","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.vaccine.2008.11.066","article-title":"An avian cell line designed for production of highly attenuated viruses","volume":"27","author":"Jordan","year":"2009","journal-title":"Vaccine"},{"key":"ref_134","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1016\/j.vaccine.2016.10.043","article-title":"The EB66\u00ae cell line as a valuable cell substrate for MVA-based vaccines production","volume":"34","author":"David","year":"2016","journal-title":"Vaccine"},{"key":"ref_135","doi-asserted-by":"publisher","first-page":"P52","DOI":"10.1186\/1753-6561-5-S8-P52","article-title":"Avian cell line\u2014Technology for large scale vaccine production","volume":"5","author":"Kraus","year":"2011","journal-title":"BMC Proc."},{"key":"ref_136","unstructured":"Mayr, A. (2004). Genetically Engineered Virus for Use in the Propagation of Preferential Cells. (6682743 B2), U.S. Patent."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Jordan, I., Lohr, V., Genzel, Y., Reichl, U., and Sandig, V. (2013). Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara. Microorganisms, 1.","DOI":"10.3390\/microorganisms1010100"},{"key":"ref_138","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.biologicals.2010.11.005","article-title":"A chemically defined production process for highly attenuated poxviruses","volume":"39","author":"Jordan","year":"2011","journal-title":"Biologicals"},{"key":"ref_139","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12250-020-00250-1","article-title":"Freeze-Drying Formulations Increased the Adenovirus and Poxvirus Vaccine Storage Times and Antigen Stabilities","volume":"36","author":"Chen","year":"2021","journal-title":"Virol. Sin."},{"key":"ref_140","doi-asserted-by":"publisher","first-page":"eadf1782","DOI":"10.1126\/scitranslmed.adf1782","article-title":"Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection","volume":"15","author":"Hou","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Leung-Theung-Long, S., Gouanvic, M., Coupet, C.A., Ray, A., Tupin, E., Silvestre, N., Marchand, J.B., Schmitt, D., Hoffmann, C., and Klein, M. (2015). A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143552"},{"key":"ref_142","doi-asserted-by":"publisher","first-page":"17286","DOI":"10.1038\/s41598-017-17587-5","article-title":"Boosting with recombinant MVA expressing M. tuberculosis \u03b1-crystallin antigen augments the protection imparted by BCG against tuberculosis in guinea pigs","volume":"7","author":"Nangpal","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e02182-16","DOI":"10.1128\/JVI.02182-16","article-title":"HIV\/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates","volume":"91","author":"Perdiguero","year":"2017","journal-title":"J. Virol."},{"key":"ref_144","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.vaccine.2016.12.060","article-title":"DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies","volume":"35","author":"Chege","year":"2017","journal-title":"Vaccine"},{"key":"ref_145","doi-asserted-by":"publisher","first-page":"15711","DOI":"10.1038\/ncomms15711","article-title":"Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge","volume":"8","author":"Bradley","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_146","doi-asserted-by":"publisher","first-page":"e02035-17","DOI":"10.1128\/JVI.02035-17","article-title":"Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates","volume":"92","author":"Saunders","year":"2018","journal-title":"J. Virol."},{"key":"ref_147","doi-asserted-by":"publisher","first-page":"e01529-18","DOI":"10.1128\/JVI.01529-18","article-title":"Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost","volume":"93","author":"Asbach","year":"2019","journal-title":"J. Virol."},{"key":"ref_148","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.3389\/fimmu.2019.02941","article-title":"Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses","volume":"10","author":"Perdiguero","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_149","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3389\/fimmu.2019.02793","article-title":"The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1","volume":"10","author":"Raman","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"L\u00e9vy, Y., Lacabaratz, C., Ellefsen-Lavoie, K., St\u00f6hr, W., Leli\u00e8vre, J.D., Bart, P.A., Launay, O., Weber, J., Salzberger, B., and Wiedemann, A. (2020). Optimal priming of poxvirus vector (NYVAC)based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03\/ ANRS VAC20 Phase I\/II Trial. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008522"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"G\u00f3mez, C.E., Perdiguero, B., Usero, L., Marcos-Villar, L., Miralles, L., Leal, L., Sorzano, C.\u00d3.S., S\u00e1nchez-Corzo, C., Plana, M., and Garc\u00eda, F. (2021). Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen. Vaccines, 9.","DOI":"10.3390\/vaccines9090959"},{"key":"ref_152","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.omtm.2021.04.018","article-title":"Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines","volume":"21","author":"Wee","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_153","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.antiviral.2018.03.004","article-title":"Improved immune response against HIV-1 Env antigen by enhancing EEV production via a K151E mutation in the A34R gene of replication-competent vaccinia virus Tiantan","volume":"153","author":"Yu","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_154","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1128\/JVI.01513-18","article-title":"Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC","volume":"93","author":"Kibler","year":"2019","journal-title":"J. Virol."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"P\u00e9rez, P., Mar\u00edn, M.Q., L\u00e1zaro-Fr\u00edas, A., Sorzano, C.\u00d3.S., Di Pilato, M., G\u00f3mez, C.E., Esteban, M., and Garc\u00eda-Arriaza, J. (2019). An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV\/AIDS Vaccine Design. Vaccines, 7.","DOI":"10.3390\/vaccines7040208"},{"key":"ref_156","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1038\/s41467-023-40430-7","article-title":"Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques","volume":"14","author":"Bollimpelli","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_157","doi-asserted-by":"publisher","first-page":"1187193","DOI":"10.3389\/fcimb.2023.1187193","article-title":"An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses","volume":"13","author":"Falqui","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Lorenzo, M.M., Mar\u00edn-L\u00f3pez, A., Chiem, K., Jimenez-Cabello, L., Ullah, I., Utrilla-Trigo, S., Calvo-Pinilla, E., Lorenzo, G., Moreno, S., and Ye, C. (2023). Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models. Vaccines, 11.","DOI":"10.20944\/preprints202305.0218.v1"},{"key":"ref_159","doi-asserted-by":"publisher","first-page":"914969","DOI":"10.3389\/fimmu.2022.914969","article-title":"V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques","volume":"13","author":"Styles","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_160","doi-asserted-by":"publisher","first-page":"eabl4102","DOI":"10.1126\/sciimmunol.abl4102","article-title":"A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques","volume":"7","author":"Sahoo","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Wilken, L., Stelz, S., Agac, A., Sutter, G., Prajeeth, C.K., and Rimmelzwaan, G.F. (2023). Recombinant Modified Vaccinia Virus Ankara Expressing a Glycosylation Mutant of Dengue Virus NS1 Induces Specific Antibody and T-Cell Responses in Mice. Vaccines, 11.","DOI":"10.3390\/vaccines11040714"},{"key":"ref_162","doi-asserted-by":"publisher","first-page":"17385","DOI":"10.1038\/s41598-018-35724-6","article-title":"A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice","volume":"8","author":"Carlos","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_163","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41541-020-0191-8","article-title":"The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates","volume":"5","author":"Prow","year":"2020","journal-title":"npj Vaccines"},{"key":"ref_164","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.vaccine.2019.02.063","article-title":"Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates","volume":"37","author":"Zhan","year":"2019","journal-title":"Vaccine"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez de Oya, N., P\u00e9rez, P., Bl\u00e1zquez, A.B., Escribano-Romero, E., Esteban, M., Saiz, J.C., Garc\u00eda-Arriaza, J., and Mar-t\u00edn-Acebes, M.A. (2022). Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara. Pharmaceuticals, 15.","DOI":"10.3390\/ph15030354"},{"key":"ref_166","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.vaccine.2016.02.042","article-title":"Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens","volume":"34","author":"Volz","year":"2016","journal-title":"Vaccine"},{"key":"ref_167","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3389\/fimmu.2018.01756","article-title":"Immunogenicity and protection after vaccination with a modified vaccinia virus Ankara-vectored yellow fever vaccine in the hamster model","volume":"9","author":"Julander","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_168","doi-asserted-by":"publisher","first-page":"1177324","DOI":"10.3389\/fimmu.2023.1177324","article-title":"Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice","volume":"14","author":"Beicht","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_169","doi-asserted-by":"publisher","first-page":"1182963","DOI":"10.3389\/fimmu.2023.1182963","article-title":"A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection","volume":"14","author":"Kubinski","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arriaza, J., Esteban, M., and L\u00f3pez, D. (2021). Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091122"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Buttigieg, K.R., Dowall, S.D., Findlay-Wilson, S., Miloszewska, A., Rayner, E., Hewson, R., and Carroll, M.W. (2014). A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091516"},{"key":"ref_172","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41541-022-00512-x","article-title":"A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection","volume":"7","author":"Malherbe","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_173","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1128\/JVI.00363-18","article-title":"Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins","volume":"92","author":"Ljungberg","year":"2018","journal-title":"J. Virol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Rahim, M.N., Wee, E.G., He, S., Audet, J., Tierney, K., Moyo, N., Hannoun, Z., Crook, A., Baines, A., and Korber, B. (2019). Complete protection of the BALB\/c and C57BL\/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007564"},{"key":"ref_175","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1016\/j.vaccine.2019.04.070","article-title":"Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice","volume":"37","author":"Xie","year":"2019","journal-title":"Vaccine"},{"key":"ref_176","doi-asserted-by":"publisher","first-page":"11384","DOI":"10.1038\/s41598-023-38010-2","article-title":"Immunogenicity of poxvirus-based vaccines against Nipah virus","volume":"13","author":"Lo","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_177","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Langenmayer, M.C., Luelf-Averhoff, A.T., Marr, L., Jany, S., Freudenstein, A., Adam-Neumair, S., Tscherne, A., Fux, R., Rojas, J.J., and Blutke, A. (2023). Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice. Pathogens, 12.","DOI":"10.3390\/pathogens12070867"},{"key":"ref_179","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41541-023-00620-2","article-title":"Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs","volume":"8","author":"Vatzia","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_180","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41593-022-01242-y","article-title":"Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate","volume":"26","author":"Villadiego","year":"2023","journal-title":"Nat. Neurosci."},{"key":"ref_181","doi-asserted-by":"publisher","first-page":"747866","DOI":"10.3389\/fimmu.2021.747866","article-title":"Single Immunization of a Vaccine Vectored by a Novel Recombinant Vaccinia Virus Affords Effective Protection Against Respiratory Syncytial Virus Infection in Cotton Rats","volume":"12","author":"Russell","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_182","doi-asserted-by":"publisher","first-page":"841471","DOI":"10.3389\/fimmu.2022.841471","article-title":"A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection","volume":"13","author":"Endt","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Alharbi, N.K., Aljamaan, F., Aljami, H.A., Alenazi, M.W., Albalawi, H., Almasoud, A., Alharthi, F.J., Azhar, E.I., Barhoumi, T., and Bosaeed, M. (2022). Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels. Vaccines, 10.","DOI":"10.3390\/vaccines10081330"},{"key":"ref_184","doi-asserted-by":"publisher","first-page":"100685","DOI":"10.1016\/j.xcrm.2022.100685","article-title":"Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine","volume":"3","author":"Weskamm","year":"2022","journal-title":"Cell Rep. Med."},{"key":"ref_185","first-page":"40198","article-title":"Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform","volume":"3","author":"Chiuppesi","year":"2020","journal-title":"Res. Sq."},{"key":"ref_186","doi-asserted-by":"publisher","first-page":"e2026207118","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_187","doi-asserted-by":"publisher","first-page":"845887","DOI":"10.3389\/fimmu.2022.845887","article-title":"Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2","volume":"13","author":"Mooij","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_188","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.ymthe.2021.10.008","article-title":"Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection","volume":"30","author":"Boulton","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_189","doi-asserted-by":"publisher","first-page":"824728","DOI":"10.3389\/fimmu.2021.824728","article-title":"A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection","volume":"12","author":"Zamora","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_190","doi-asserted-by":"publisher","first-page":"1160065","DOI":"10.3389\/fimmu.2023.1160065","article-title":"Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2\/COVID-19 vaccine candidate","volume":"14","author":"Perdiguero","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Kalodimou, G., Jany, S., Freudenstein, A., Schwarz, J.H., Limpinsel, L., Rohde, C., Kupke, A., Becker, S., Volz, A., and Tscherne, A. (2023). Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice. Viruses, 15.","DOI":"10.3390\/v15051180"},{"key":"ref_192","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41541-023-00640-y","article-title":"Synthetic multi-antigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants","volume":"8","author":"Wussow","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"967019","DOI":"10.3389\/fmicb.2022.967019","article-title":"An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants","volume":"13","author":"Ishigaki","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_194","doi-asserted-by":"publisher","first-page":"e2202069119","DOI":"10.1073\/pnas.2202069119","article-title":"Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection","volume":"119","author":"Americo","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_195","doi-asserted-by":"publisher","first-page":"e00389-22","DOI":"10.1128\/jvi.00389-22","article-title":"Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease","volume":"96","author":"Deschambault","year":"2022","journal-title":"J. Virol."},{"key":"ref_196","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.4049\/jimmunol.2101076","article-title":"T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I\/II ANRS VRI01 Trial","volume":"208","author":"Richert","year":"2022","journal-title":"J. Immunol."},{"key":"ref_197","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4161\/hv.22464","article-title":"Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase i clinical trial","volume":"9","author":"Rowland","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_198","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Jordan, E., Kabir, G., Schultz, S., Silbernagl, G., Schmidt, D., Jenkins, V.A., Weidenthaler, H., Stroukova, D., Martin, B.K., and De Moerlooze, L. (2023). Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine. J. Infect. Dis., jiad108.","DOI":"10.1093\/infdis\/jiad108"},{"key":"ref_200","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S1473-3099(21)00702-7","article-title":"Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): A phase 2b, randomised, double-blind trial","volume":"22","author":"Evans","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_201","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1016\/S2666-5247(22)00027-1","article-title":"Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): An open-label and randomised, phase 1 trial","volume":"3","author":"Chiuppesi","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_202","first-page":"278","article-title":"Stability of vaccinia-vectored recombinant oral rabies vaccine under field conditions: A 3-year study","volume":"75","author":"Hermann","year":"2011","journal-title":"Can. J. Vet. Res."},{"key":"ref_203","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.coi.2021.03.008","article-title":"Ebola virus disease: Current vaccine solutions","volume":"71","author":"Tomori","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_204","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.vaccine.2013.03.042","article-title":"Reflections on the Early Development of Poxvirus Vectors","volume":"31","author":"Moss","year":"2013","journal-title":"Vaccine"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/8\/1742\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:33:47Z","timestamp":1760128427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/8\/1742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":204,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["v15081742"],"URL":"https:\/\/doi.org\/10.3390\/v15081742","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]}}}